BCR and rheumatoid arthritis: We recently reported on the ability of PRT062607 (also called P505-15) to suppress BCR-mediated signaling and cellular activation in healthy volunteer whole blood, and demonstrated dose-dependent reductions of inflammation in rodent models of RA (Coffey et al. 2011).